2,4-Dinitrophenol: A threat to Chinese body-conscious groups  by Lee, Han Chih Hencher et al.
Available online at www.sciencedirect.comScienceDirect
Journal of the Chinese Medical Association 77 (2014) 443e445
www.jcma-online.comCase Report
2,4-Dinitrophenol: A threat to Chinese body-conscious groups
Han Chih Hencher Lee, Chun Yiu Law, Mo Lung Chen, Ying Hoo Lam, Albert Yan Wo Chan,
Tony Wing Lai Mak*
Hospital Authority Toxicology Reference Laboratory, Princess Margaret Hospital, Hong Kong, China
Received March 20, 2012; accepted February 20, 2013Abstract2,4-Dinitrophenol (2,4-DNP), a yellowish compound, has historically been used in the manufacture of dyes, explosives, and fungicides. As it
uncouples mitochondrial oxidative phosphorylation, the compound was also used as an antiobesity agent early in the past century. The com-
pound was subsequently banned by the United States Food and Drug Administration in 1938 due to its potentially fatal adverse effects, including
hyperthermia, cataract, agranulocytosis, hepatoxicity, nephrotoxicity, and cardiotoxicity. However, the popularity of 2,4-DNP as a slimming aid
has appeared to increase again in recent years. The Hong Kong Hospital Authority Toxicology Reference Laboratory recently confirmed two
cases of self-administered 2,4-DNP with different clinical presentations to hospitals in the area. Here we describe those two cases, in an attempt
to underscore the potential of misuse of this substance by body-conscious groups among the Chinese population.
Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Association. All rights reserved.
Keywords: 2,4-dinitrophenol; bodybuilding; slimming; uncoupling agents1. Introduction
2,4-Dinitrophenol (2,4-DNP) is a crystalline solid that is
slightly soluble in water, and more soluble in organic solvents
such as ethanol and ether.1 The chemical has been used as a
component of explosives and fungicides; with its yellow color,
it has also been used in fabric and food colorings since the late
19th century.2
Subacute and acute 2,4-DNP compound poisoning cases
were reported among workers in munitions factories during
World War I, which included fatalities.3 Clinical symptoms
include anorexia, nausea, vomiting, headache, dizziness, res-
piratory distress, as well as generalized weakness and weight
loss. Profuse yellow-tinted sweating is pathognomonic of thisConflicts of interest: The authors declare that there are no conflicts of interest
related to the subject matter or materials discussed in this article.
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1726-4901/Copyright © 2014 Elsevier Taiwan LLC and the Chinese Medical Asspoisoning.4 Hyperthermia was a commonly observed feature
insofar as the body temperature could rise up to 43C in fatal
cases. Rigor mortis set in promptly after death, and post
mortem examination showed pulmonary edema with a possible
yellowish tint of the organs.3
Since 1933, the compound had been marketed as an anti-
obesity agent promising substantial benefits. The use of this
compound was particularly attractive when apparently only fat
and carbohydrates were broken down, but not proteins, with
no change in nitrogen excretion caused by 2,4-DNP.5 This all
occurred despite the warning issued by the Council on Phar-
macy and Chemistry concerning the potential toxicities of the
compound,6 which inevitably resulted in some instances of
uncontrolled administration.7 At the same time, the spectrum
of adverse effects from the use of 2,4-DNP expanded: these
included maculopapular erythematous skin eruptions in 7% of
the cases,5 in addition to gastrointestinal discomfort, cataract,
hepatoxicity, nephrotoxicity, cardiotoxicity, and agranulocy-
tosis.7,8 There were deaths reported following administration
of the compound within the recommended dosage,7 and the
chemical was finally banned in 1938.2ociation. All rights reserved.
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as a slimming agent is again on the rise.4,9 Here we report two
local cases of 2,4-DNP misuse in Hong Kong Chinese patients
referred to our laboratory, in which the adverse effects of the
compound led to patient hospitalization.
2. Case reports2.1. Case 1The 30-year-old male patient, who had a history of good
health, was referred by his general practitioner to the hospital.
He presented with maculopapular rash on his forehead as well
as shortness of breath. He described a recent history of
ingesting a type of bodybuilding pill obtained from his friend
for 10 days, which caused him to sweat excessively when
taken together with carbohydrate-rich food, in addition to
another over-the-counter cold medication. Upon presentation
his rash became generalized, involving his trunk, limbs, neck,
and oral mucosa with skin sloughing. His blood pressure,
pulse, and body temperature were normal (119/68 mmHg, 61
beats/minute, 36.0C, respectively), and he had an increased
respiratory rate of 18 breaths/minute. Liver and renal function
tests and complete blood picture were grossly normal. Muscle
enzymes were not measured. The bodybuilding pill was sent to
the Hospital Authority Toxicology Reference Laboratory for
chemical analysis, in which 2,4-DNP was detected by both
high-performance liquid chromatography-diode array detector
(HPLC-DAD) and gas chromatography-mass spectrometry; no
other known drug or toxin was detected. The 2,4-DNP content
of the pill was subsequently estimated by HPLC-DAD to be
72 mg/pill. The patient was discharged on Day 2, and he never
returned for follow-up.2.2. Case 2The 25-year-old female patient, with a past history of Graves'
disease in remission, complained of fever and muscle pain. She
gave a recent history of taking a body slimming pill obtained
from a friend for one month, who also reported similar com-
plaints upon using the pill. On admission she was observed to
have tachycardia with a heart rate of 114 beats/minute and
tachypneawith a respiratory rate of 20 breaths/minute. Her body
temperature was 39.7C. Her serum-free thyroxine level was
12.8 pmol/L (reference interval 12.0e22.0 pmol/L), while her
serum thyroid-stimulating hormone level was decreased to
0.14 mIU/L (0.27e4.20 mIU/L), which subsequently returned
to normal (1.56 mIU/L) after 1 month without treatment. Her
muscle enzymeswere moderately elevated on admission: serum
creatine kinase and lactate dehydrogenase concentrations were
696 U/L (42e190 U/L) and 403 U/L (211e370 U/L), respec-
tively, which further increased to 915 U/L and 768 U/L and
returned to normal after onemonth (55U/L; 272U/L). Liver and
renal function tests and complete blood picture were grossly
normal. The patient's body slimming pills were sent to the
Hospital Authority Toxicology Reference Laboratory and
analysis by HPLC-DAD and liquid chromatography-ion trap-time-of-flight mass spectrometry showed the content of 2,4-
DNP; no other known drug or toxin was detected. Quantita-
tive estimation of the 2,4-DNP content was not performed due to
lack of further specimen. The patient was given paracetamol
500 mg every 4 hours for her hyperthermia and propranolol
10 mg three times daily for her tachycardia. Her symptoms
subsided and she was discharged on Day 4. She was asymp-
tomatic at her follow-up visit one month later.
3. Discussion
In this report we describe two cases of misuse of 2,4-DNP
from an unknown source occurring in a Chinese population
within four months. Although the causal relationships were
difficult to establish, the adverse effects were temporally
consistent with the use of 2,4-DNP, which appeared when use of
the compound was commenced and subsided upon termination
of use. It was a major limitation that no concurrent biological
sample in which the presence of the compound could be
confirmed, was available, and therefore we could only rely on
the drug history provided by the patients. The self-administered
2,4-DNP was associated with different clinical presentations in
the two cases: one patient presented with generalized skin rash
and the other with hyperthermia and muscle injury. Both pre-
sentations are known adverse reactions of 2,4-DNP use. The
latter was associated with its thermogenic property whereas the
former was likely to be related to the immunogenic reactions
towards the compound in vivo. Although the causal role of the
compound for the rash in our patient could not be firmly
established, a series of cases presenting with cutaneous re-
actions towards 2,4-DNP were reported in the 1930s, and it was
estimated that 7% of exposed individuals were affected.10,11
The compound was later confirmed to be a potent hapten that
could produce hypersensitivity via the immunoglobulin
E-mediated immune response.12 It is now known that the
compound acts by uncoupling mitochondrial oxidative phos-
phorylation: by increasing the proton conductance of mito-
chondria, and thus the basal leak pathway from cytosol into the
matrix, synthesis of adenosine triphosphate is uncoupled and
energy is dissipated as heat rather than in the high-energy
phosphate bonds.13 The hyperthermia produced then leads to
the subsequent damage to muscle and organs, and other symp-
toms related to increased body temperature.
The high potential of 2,4-DNP toxicity is two-fold. First of
all, with its claim of having a fat-burning effect without the
need of dietary control, it attracts the immense interest of
those body-conscious groups in society: these include teenage
to middle-aged females, or even males, who are paying
particular attention to body slimming, as well as bodybuilders
who are similarly concerned about losing fat at the same time
as muscle building. Secondly, the dose recommended for its
fat-burning effect is close to that producing dangerous adverse
reactions, thus allegedly having a narrow “therapeutic index”,
as described by Hsiao et al.9 Moreover, the dose required to
produce fatality can decrease abruptly with an increase in
body temperature so that the risks are particularly high in
those body-conscious groups who are likely to exercise
445H.C.H. Lee et al. / Journal of the Chinese Medical Association 77 (2014) 443e445vigorously.14 The clinical presentation can therefore mimic
heat exhaustion or heat stroke as well as other types of
poisoning. Management of 2,4-DNP poisoning requires
aggressive supportive measures. Consequently, cooling is
important in patients with hyperthermia, whereas dialysis and
hemoperfusion are not effective. If conventional cooling
measures such as ice-baths and sedation with benzodiazepines
are inadequate to reduce the body temperature, the use of
dantrolene is also suggested by some groups.15,16 Although
people often survived after taking the compound, a number of
fatal cases have been reported in the literature.4,9,15,17
As a slimming agent, 2,4-DNP has reportedly resurfaced,
probably with the increasing convenience of purchase over the
Internet.4,9 In 2003, 70 years after Cutting et al1,5 reported
about the fat-burning properties of 2,4-DNP, the Food Stan-
dards Agency in the UK issued an urgent advisory about the
use of 2,4-DNP when a Finnish body-builder was hospitalized
after taking the compound. Our two cases demonstrate that the
use of the compound can similarly be a threat to Chinese
populations where consciousness of body image is apparent.
Frontline clinicians should raise awareness for 2,4-DNP
poisoning especially when the high-risk, figure-minded, and
bodybuilding groups are encountered.
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